Viviane Nascimento Da Conceição
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
A Supergene-Linked Estrogen Receptor Drives Alternative Phenotypes in a Polymorphic Songbird
A supergene-linked estrogen receptor drives alternative phenotypes in a polymorphic songbird Jennifer R. Merritta,1, Kathleen E. Grogana, Wendy M. Zinzow-Kramera, Dan Sunb, Eric A. Ortlundc, Soojin V. Yib, and Donna L. Maneya aDepartment of Psychology, Emory University, Atlanta, GA 30322; bSchool of Biological Sciences, Georgia Institute of Technology, Atlanta, GA 30332; and cDepartment of Biochemistry, Emory University, Atlanta, GA 30322 Edited by Gene E. Robinson, University of Illinois at Urbana–Champaign, Urbana, IL, and approved July 8, 2020 (received for review June 3, 2020) Behavioral evolution relies on genetic changes, yet few behaviors tan-striped (TS) morph are homozygous for the standard ar- can be traced to specific genetic sequences in vertebrates. Here we rangement, ZAL2 (13, 14) (Fig. 1A). The rearrangement is provide experimental evidence showing that differentiation of a maintained in the population because of the species’ unique dis- single gene has contributed to the evolution of divergent behav- assortative mating system; nearly every breeding pair consists of ioral phenotypes in the white-throated sparrow, a common back- one individual of each morph (15). Because almost all WS birds yard songbird. In this species, a series of chromosomal inversions are heterozygous for ZAL2m (15, 16), this mating system keeps has formed a supergene that segregates with an aggressive phe- ZAL2m in a near-constant state of heterozygosity (Fig. 1B), pro- notype. The supergene has captured ESR1, the gene that encodes foundly suppressing recombination and causing it to differentiate estrogen receptor α (ERα); as a result, this gene is accumulating from ZAL2 (15, 17). changes that now distinguish the supergene allele from the stan- The rearranged region of ZAL2m in white-throated sparrows dard allele. -
Binnenwerk Cindy Postma.Indd
CHAPTER 6 Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression Gut 2009, 58: 79-89 Beatriz Carvalho Cindy Postma Sandra Mongera Erik Hopmans Sharon Diskin Mark A. van de Wiel Wim van Criekinge Olivier Thas Anja Matthäi Miguel A. Cuesta Jochim S. Terhaar sive Droste Mike Craanen Evelin Schröck Bauke Ylstra Gerrit A. Meijer 104 | Chapter 6 Abstract Objective: This study aimed to identify the oncogenes at 20q involved in colorectal adenoma to carcinoma progression by measuring the effect of 20q gain on mRNA expression of genes in this amplicon. Methods: Segmentation of DNA copy number changes on 20q was performed by array CGH in 34 non-progressed colorectal adenomas, 41 progressed adenomas (i.e. adenomas that present a focus of cancer) and 33 adenocarcinomas. Moreover, a robust analysis of altered expression of genes in these segments was performed by microarray analysis in 37 adenomas and 31 adenocarcinomas. Protein expression was evaluated by immunohistochemistry on tissue microarrays. Results: The genes C20orf24, AURKA, RNPC1, TH1L, ADRM1, C20orf20 and TCFL5, mapping at 20q were signifi cantly overexpressed in carcinomas compared to adenomas as consequence of copy number gain of 20q. Conclusion: This approach revealed C20orf24, AURKA, RNPC1, TH1L, ADRM1, C20orf20 and TCFL5 genes to be important in chromosomal instability-related adenoma to carcinoma progression. These genes therefore may serve as highly specifi c biomarkers for colorectal cancer with potential clinical applications. Putative oncogenes at chromosome 20q in colorectal carcinogenesis | 105 Introduction The majority of cancers are epithelial in origin and arise through a stepwise progression from normal cells, through dysplasia, into malignant cells that invade surrounding tissues and have metastatic potential. -
A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated. -
Regular Article
Regular Article LYMPHOID NEOPLASIA Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells Duohui Jing,1,2 Vivek A. Bhadri,1,2 Dominik Beck,2,3 Julie A. I. Thoms,2,3 Nurul A. Yakob,1,2 Jason W. H. Wong,2,3 Kathy Knezevic,2,3 John E. Pimanda,2,3,4 and Richard B. Lock1,2 1Children’s Cancer Institute Australia for Medical Research, 2Lowy Cancer Research Centre, and the 3Prince of Wales Clinical School, University of New South Wales, Sydney, Australia; and 4Department of Haematology, Prince of Wales Hospital, Sydney, Australia Key Points Glucocorticoids are critical components of combination chemotherapy regimens in pediatric acute lymphoblastic leukemia (ALL). The proapoptotic BIM protein is an important • The glucocorticoid receptor mediator of glucocorticoid-induced apoptosis in normal and malignant lymphocytes, coordinately regulates the whereas the antiapoptotic BCL2 confers resistance. The signaling pathways regulating BIM antiapoptotic BCL2 and and BCL2 expression in glucocorticoid-treated lymphoid cells remain unclear. In this study, proapoptotic BIM genes in pediatric ALL patient-derived xenografts (PDXs) inherently sensitive or resistant to pediatric ALL cells in vivo. glucocorticoids were exposed to dexamethasone in vivo. Microarray analysis showed KLF13 MYB • GR binding at a novel intronic that and gene expression changes were significantly greater in dexamethasone- sensitive than -resistant PDXs. Chromatin immunoprecipitation (ChIP) analysis detected region is associated with glucocorticoid receptor (GR) binding at the KLF13 promoter to trigger KLF13 expression BIM transcription and only in sensitive PDXs. Next, KLF13 bound to the MYB promoter, deactivating MYB ex- dexamethasone sensitivity in pression only in sensitive PDXs. -
WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT (51) International Patent Classification: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, C12Q 1/68 (2018.01) A61P 31/18 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, C12Q 1/70 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/US2018/056167 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 16 October 2018 (16. 10.2018) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 62/573,025 16 October 2017 (16. 10.2017) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, ΓΕ , IS, IT, LT, LU, LV, (71) Applicant: MASSACHUSETTS INSTITUTE OF MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TECHNOLOGY [US/US]; 77 Massachusetts Avenue, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Cambridge, Massachusetts 02139 (US). -
Modulating Antiviral Response Via CRISPR–Cas Systems
viruses Review Immunity and Viral Infections: Modulating Antiviral Response via CRISPR–Cas Systems Sergey Brezgin 1,2,3,† , Anastasiya Kostyusheva 1,†, Ekaterina Bayurova 4 , Elena Volchkova 5, Vladimir Gegechkori 6 , Ilya Gordeychuk 4,7, Dieter Glebe 8 , Dmitry Kostyushev 1,3,*,‡ and Vladimir Chulanov 1,3,5,‡ 1 National Medical Research Center of Tuberculosis and Infectious Diseases, Ministry of Health, 127994 Moscow, Russia; [email protected] (S.B.); [email protected] (A.K.); [email protected] (V.C.) 2 Institute of Immunology, Federal Medical Biological Agency, 115522 Moscow, Russia 3 Scientific Center for Genetics and Life Sciences, Division of Biotechnology, Sirius University of Science and Technology, 354340 Sochi, Russia 4 Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia; [email protected] (E.B.); [email protected] (I.G.) 5 Department of Infectious Diseases, Sechenov University, 119991 Moscow, Russia; [email protected] 6 Department of Pharmaceutical and Toxicological Chemistry, Sechenov University, 119991 Moscow, Russia; [email protected] 7 Department of Organization and Technology of Immunobiological Drugs, Sechenov University, 119991 Moscow, Russia 8 National Reference Center for Hepatitis B Viruses and Hepatitis D Viruses, Institute of Medical Virology, Justus Liebig University of Giessen, 35392 Giessen, Germany; [email protected] * Correspondence: [email protected] † Co-first authors. Citation: Brezgin, S.; Kostyusheva, ‡ Co-senior authors. A.; Bayurova, E.; Volchkova, E.; Gegechkori, V.; Gordeychuk, I.; Glebe, Abstract: Viral infections cause a variety of acute and chronic human diseases, sometimes resulting D.; Kostyushev, D.; Chulanov, V. Immunity and Viral Infections: in small local outbreaks, or in some cases spreading across the globe and leading to global pandemics. -
Identification of Potential Key Genes and Pathway Linked with Sporadic Creutzfeldt-Jakob Disease Based on Integrated Bioinformatics Analyses
medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Identification of potential key genes and pathway linked with sporadic Creutzfeldt-Jakob disease based on integrated bioinformatics analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract Sporadic Creutzfeldt-Jakob disease (sCJD) is neurodegenerative disease also called prion disease linked with poor prognosis. The aim of the current study was to illuminate the underlying molecular mechanisms of sCJD. The mRNA microarray dataset GSE124571 was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were screened. -
"Description"" ""Generatio"
TABLE S4 "ID ""Description"" ""GeneRatio"" ""BgRatio"" ""pvalue"" ""p.adjust"" ""qvalue"" ""geneID"" ""Count""" "GO:0003712 ""GO:0003712"" ""transcription coregulator activity"" ""84/1859"" ""454/22744"" 9.49597175224444e-13 9.80933882006851e-10 8.20651874588704e-10 ""Ncoa2/Zfp451/Dhx9/Hnrnpu/Cited2/Ncoa7/Ccar1/ Sirt1/Arid5b/Sirt6/Med1/Rara/Atxn7l3/Ddx5/Wbp2/Hdac9/Zmynd11/Cdyl/ Mier3/Sfmbt1/Gata4/Med4/Basp1/Zfpm2/Zhx2/Ddx17/Mkl2/Hes1/Nrip1/Usp16/ Elob/Rrp1b/Rxrb/Kat2b/Mta3/Hsbp1l1/Tle4/Sfr1/Eid1/Cops2/Sox12/Raly/ Ncoa6/Rbm39/Lpin3/Skil/Jade1/Maml3/Supt20/Med12l/Hdgf/Glmp/Nfib/Jun/ Pex14/Rere/Psmd9/Ncor2/Trim24/Ruvbl1/Rybp/Bhlhe40/Atf7ip/Ube3a/Mef2a/ Nrg1/Rbpms/Cnot7/Sin3b/Pou4f2/Pkn1/Cdyl2/Taf5l/Irf2bp2/Birc2/Yap1/ Skor1/Tfdp2/Rad54l2/Ctnnb1/Limd1/Med14/Rap2c/Tbl1x"" 84" "GO:0003779 ""GO:0003779"" ""actin binding"" ""65/1859"" ""414/22744"" 2.57546466939442e-07 8.86818334494813e-05 7.41914559148359e-05 ""Actr3/Cxcr4/Hnrnpu/Enah/Utrn/Epb41l2/Marcks/Ctnna3/Eef2/Pawr/ Ccdc88a/Anxa6/Gas7/Lasp1/Tns4/Syne2/Sipa1l1/Syne3/Phactr1/Enc1/Pxk/ Vcl/Ang/Myo10/Mtss1/Triobp/Mkl2/Afdn/Daam2/Svil/Ctnna1/Synpo/Myo5b/ Nrap/Ablim1/Shtn1/Fmnl2/Itprid2/Ino80/Pfn2/Myoz2/Pdlim5/Cap1/Macf1/ Epb41/Wasf2/Myom3/Ywhah/Coro1c/Ssh1/Hip1/Ppp1r9a/Wasl/Ctnna2/Mical3/ Eps8/Tlnrd1/Myom2/Klhl2/Sntb2/Spire2/Coro2b/Clasp2/Hdac6/Diaph2"" 65" "GO:0046332 ""GO:0046332"" ""SMAD binding"" ""22/1859"" ""84/22744"" 6.87941766027971e-07 0.000177660961076723 0.000148631628923412 ""Bmpr2/Cited2/Usp15/Ddx5/Axin2/Ppm1a/Yy1/Gata4/Tgif1/Ldlrad4/Smad7/ Acvr2a/Pmepa1/Skil/Trim33/Jun/Mef2a/Ipo7/Skor1/Rnf111/Tcf12/Ctnnb1"" -
(12) United States Patent (10) Patent No.: US 8.440,393 B2 Birrer Et Al
USOO8440393B2 (12) United States Patent (10) Patent No.: US 8.440,393 B2 Birrer et al. (45) Date of Patent: May 14, 2013 (54) PRO-ANGIOGENIC GENES IN OVARIAN OTHER PUBLICATIONS TUMORENDOTHELIAL CELL, SOLATES Boyd (The Basic Science of Oncology, 1992, McGraw-Hill, Inc., p. (75) Inventors: Michael J. Birrer, Mt. Airy, MD (US); 379). Tomas A. Bonome, Washington, DC Tockman et al. (Cancer Res., 1992, 52:2711s-2718s).* (US); Anil Sood, Pearland, TX (US); Pritzker (Clinical Chemistry, 2002, 48: 1147-1150).* Chunhua Lu, Missouri City, TX (US) Benedict et al. (J. Exp. Medicine, 2001, 193(1) 89-99).* Jiang et al. (J. Biol. Chem., 2003, 278(7) 4763-4769).* (73) Assignees: The United States of America as Matsushita et al. (FEBS Letters, 1999, vol. 443, pp. 348-352).* Represented by the Secretary of the Singh et al. (Glycobiology, 2001, vol. 11, pp. 587-592).* Department of Health and Human Abbosh et al. (Cancer Res. Jun. 1, 2006 66:5582-55.91 and Supple Services, Washington, DC (US); The mental Figs. S1-S7).* University of MD Anderson Cancer Zhai et al. (Chinese General Practice Aug. 2008, 11(8A): 1366 Center, Houston, TX (US) 1367).* Lu et al. (Cancer Res. Feb. 15, 2007, 64(4): 1757-1768).* (*) Notice: Subject to any disclaimer, the term of this Bagnato et al., “Activation of Mitogenic Signaling by Endothelin 1 in patent is extended or adjusted under 35 Ovarian Carcinoma Cells', Cancer Research, vol. 57, pp. 1306-1311, U.S.C. 154(b) by 194 days. 1997. Bouras et al., “Stanniocalcin 2 is an Estrogen-responsive Gene (21) Appl. -
Supplemental Table 3 Site ID Intron Poly(A) Site Type NM/KG Inum
Supplemental Table 3 Site ID Intron Poly(A) site Type NM/KG Inum Region Gene ID Gene Symbol Gene Annotation Hs.120277.1.10 chr3:170997234:170996860 170996950 b NM_153353 7 CDS 151827 LRRC34 leucine rich repeat containing 34 Hs.134470.1.27 chr17:53059664:53084458 53065543 b NM_138962 10 CDS 124540 MSI2 musashi homolog 2 (Drosophila) Hs.162889.1.18 chr14:80367239:80329208 80366262 b NM_152446 12 CDS 145508 C14orf145 chromosome 14 open reading frame 145 Hs.187898.1.27 chr22:28403623:28415294 28404458 b NM_181832 16 3UTR 4771 NF2 neurofibromin 2 (bilateral acoustic neuroma) Hs.228320.1.6 chr10:115527009:115530350 115527470 b BC036365 5 CDS 79949 C10orf81 chromosome 10 open reading frame 81 Hs.266308.1.2 chr11:117279579:117278191 117278967 b NM_032046 12 CDS 84000 TMPRSS13 transmembrane protease, serine 13 Hs.266308.1.4 chr11:117284536:117281662 117283722 b NM_032046 9 CDS 84000 TMPRSS13 transmembrane protease, serine 13 Hs.2689.1.4 chr10:53492398:53563605 53492622 b NM_006258 7 CDS 5592 PRKG1 protein kinase, cGMP-dependent, type I Hs.280781.1.6 chr18:64715646:64829150 64715837 b NM_024781 4 CDS 79839 C18orf14 chromosome 18 open reading frame 14 Hs.305985.2.25 chr12:8983686:8984438 8983942 b BX640639 17 3UTR NA NA NA Hs.312098.1.36 chr1:151843991:151844258 151844232 b NM_003815 15 CDS 8751 ADAM15 a disintegrin and metalloproteinase domain 15 (metargidin) Hs.314338.1.11 chr21:39490293:39481214 39487623 b NM_018963 41 CDS 54014 BRWD1 bromodomain and WD repeat domain containing 1 Hs.33368.1.3 chr15:92685158:92689361 92688314 b NM_018349 6 CDS 55784 MCTP2 multiple C2-domains with two transmembrane regions 2 Hs.346736.1.21 chr2:99270738:99281614 99272414 b AK126402 10 3UTR 51263 MRPL30 mitochondrial ribosomal protein L30 Hs.445061.1.19 chr16:69322898:69290216 69322712 b NM_018052 14 CDS 55697 VAC14 Vac14 homolog (S. -
Corepressive Function of Nuclear Receptor Coactivator 2 in Androgen
Takeda et al. BMC Cancer (2016) 16:332 DOI 10.1186/s12885-016-2378-y RESEARCH ARTICLE Open Access Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen Keisuke Takeda1, Noboru Hara1,2,3*, Tsutomu Nishiyama1, Masayuki Tasaki1, Fumio Ishizaki1 and Yoshihiko Tomita1 Abstract Background: Recruitment of cofactors in the interaction of the androgen receptor (AR) and AR ligands plays a critical role in determining androgenic/antiandrogenic effects of the AR ligand on signaling, but the functions of key cofactors, including nuclear receptor coactivator (NCOA), remain poorly understood in prostate cancer cells treated with AR ligands. Methods: We examined prostate cancer cell lines LNCaP and VCaP expressing mutated and wild-type ARs, respectively, to clarify the significance of NCOAs in the effect of antiandrogens. Hydroxyflutamide showed antagonistic activity against VCaP and an agonistic effect on LNCaP. Bicalutamide served as an antagonist for both. We analyzed mRNA transcription and protein expression of NCOAs in these cells pretreated with dihydrotestosterone and thereafter treated with the mentioned antiandrogens. Transcriptional silencing of candidate NCOAs and AR was performed using small interfering RNA (siRNA). Cell proliferation was evaluated with MTT assay. Results: LNCaP treated with bicalutamide showed an about four-fold increase in the expression of NCOA2 mRNA compared to those pretreated with dihydrotestosterone alone (P <0.01). In VCaP pretreated with dihydrotestosterone, transcriptions of NCOA2 and NCOA7 were slightly increased with bicalutamide (1.96- and 2. 42-fold, respectively) and hydroxyflutamide (1.33-fold in both). With Western blotting, the expression of NCOA2 protein also increased in LNCaP cells treated with bicalutamide compared with that in control cells pretreated with dihydrotestosterone alone. -
Rattlesnake Genome Supplemental Materials 1 SUPPLEMENTAL
Rattlesnake Genome Supplemental Materials 1 1 SUPPLEMENTAL MATERIALS 2 Table of Contents 3 1. Supplementary Methods …… 2 4 2. Supplemental Tables ……….. 23 5 3. Supplemental Figures ………. 37 Rattlesnake Genome Supplemental Materials 2 6 1. SUPPLEMENTARY METHODS 7 Prairie Rattlesnake Genome Sequencing and Assembly 8 A male Prairie Rattlesnake (Crotalus viridis viridis) collected from a wild population in Colorado was 9 used to generate the genome sequence. This specimen was collected and humanely euthanized according 10 to University of Northern Colorado Institutional Animal Care and Use Committee protocols 0901C-SM- 11 MLChick-12 and 1302D-SM-S-16. Colorado Parks and Wildlife scientific collecting license 12HP974 12 issued to S.P. Mackessy authorized collection of the animal. Genomic DNA was extracted using a 13 standard Phenol-Chloroform-Isoamyl alcohol extraction from liver tissue that was snap frozen in liquid 14 nitrogen. Multiple short-read sequencing libraries were prepared and sequenced on various platforms, 15 including 50bp single-end and 150bp paired-end reads on an Illumina GAII, 100bp paired-end reads on an 16 Illumina HiSeq, and 300bp paired-end reads on an Illumina MiSeq. Long insert libraries were also 17 constructed by and sequenced on the PacBio platform. Finally, we constructed two sets of mate-pair 18 libraries using an Illumina Nextera Mate Pair kit, with insert sizes of 3-5 kb and 6-8 kb, respectively. 19 These were sequenced on two Illumina HiSeq lanes with 150bp paired-end sequencing reads. Short and 20 long read data were used to assemble the previous genome assembly version CroVir2.0 (NCBI accession 21 SAMN07738522).